Press Releases Site - Investor Navigation Corporate Profile Press Releases Events & Presentations Stock Information Stock Quote & Chart Historic Price Lookup Analyst Coverage Financial Filings SEC Filings Corporate Governance Documents & Charters Management Team Board of Directors Investor Resources Investor FAQs Investor Email Alerts Contact IR Year None20232022202120202019 Mar 14, 2023 Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results Mar 07, 2023 Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting Mar 06, 2023 Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Immune Checkpoint Inhibitors to Treat Urothelial Carcinoma Feb 28, 2023 Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference Print Page Email Alerts RSS Feeds
Year None20232022202120202019 Mar 14, 2023 Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results Mar 07, 2023 Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting Mar 06, 2023 Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Immune Checkpoint Inhibitors to Treat Urothelial Carcinoma Feb 28, 2023 Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference
Mar 07, 2023 Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting
Mar 06, 2023 Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Immune Checkpoint Inhibitors to Treat Urothelial Carcinoma
